Get the Stockscreener App
1.4807
2.07%
0.0307
Quince Therapeutics Inc stock is traded at $1.4807, with a volume of 56,796.
It is up +2.07% in the last 24 hours and down -7.50% over the past month.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing innovative precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics.
See More
Previous Close:
$1.45
Open:
$1.5
24h Volume:
56,796
Relative Volume:
0.33
Market Cap:
$64.26M
Revenue:
-
Net Income/Loss:
$-31.39M
P/E Ratio:
-1.7627
EPS:
-0.84
Net Cash Flow:
$-18.45M
1W Performance:
+5.71%
1M Performance:
-7.50%
6M Performance:
+113.56%
1Y Performance:
+15.62%
1-Day Range:
$1.44
$1.5231
1-Week Range:
$1.28
$1.5231
52-Week Range:
$0.5116
$2.45
Quince Therapeutics Inc Stock (QNCX) Company Profile
Name
Quince Therapeutics Inc
Sector
Industry
Phone
415-910-5717
Address
611 GATEWAY BLVD., SUITE 273, SOUTH SAN FRANCISCO
Compare QNCX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
QNCX
Quince Therapeutics Inc
|
1.4866 | 64.26M | 0 | -31.39M | -18.45M | -0.84 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.16 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
690.70 | 75.07B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
636.58 | 37.96B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
243.53 | 31.79B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
113.23 | 27.34B | 3.30B | -501.07M | 1.03B | -2.1146 |
Quince Therapeutics Inc Stock (QNCX) Latest News
Quince Therapeutics, Inc. (NASDAQ:QNCX) Receives $9.50 Average Price Target from Analysts - Defense World
Quince Therapeutics, Inc. (NASDAQ:QNCX) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
D. Boral Capital Reiterates "Buy" Rating for Quince Therapeutics (NASDAQ:QNCX) - MarketBeat
Quince Therapeutics to Host Investor Webinar Today Focused on Addressing the High Unmet Need in Ataxia-Telangiectasia - Business Wire
Quince Therapeutics secures USPTO nod for A-T treatment patent - MSN
D. Boral Capital Reaffirms “Buy” Rating for Quince Therapeutics (NASDAQ:QNCX) - Defense World
Quince Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference - Marketscreener.com
Quince Therapeutics secures USPTO nod for A-T treatment patent By Investing.com - Investing.com Australia
Quince Therapeutics Receives Notice of Allowance Covering Innovative Method of Use for Lead Indication Ataxia-Telangiectasia - Business Wire
Patent Victory: Quince's Rare Disease Treatment Gets Dual-Layer Protection Until 2036 - StockTitan
Ataxia Telangiectasia Market on Track for Major Expansion by 2032, According to DelveInsight | Acasti Pharma Inc., IntraBio Inc - The Globe and Mail
Earnings Coming in Better-Than-Expected As Peak Season Begins - The Globe and Mail
Meta Platforms Is Surging on Q4 Earnings. Is Meta Stock a Buy, Sell, or Hold for 2025? - The Globe and Mail
Quince Therapeutics, Inc. (NASDAQ:QNCX) Receives $9.50 Average PT from Brokerages - Defense World
Earnings To Watch: Kirby (KEX) Reports Q4 Results Tomorrow - The Globe and Mail
Quince Therapeutics to Host Investor Webinar on February 7, 2025 Focused on Addressing the High Unmet Need in Ataxia-Telangiectasia - Business Wire
Quince Therapeutics, Inc. Announces Frontiers in Neurology Publication of Long-Term Safety of EryDex in Pediatric Patients with Ataxia-Telangiectasia - Marketscreener.com
Quince Therapeutics Announces Frontiers in Neurology Publication of Long-Term Safety of EryDex in Pediatric Patients with Ataxia-Telangiectasia - Business Wire
Quince Therapeutics, Inc. (NASDAQ:QNCX) Receives $9.50 Consensus Target Price from Brokerages - MarketBeat
Quince Therapeutics Appoints Renowned Pediatric Neurologist Dr. William Whitehouse to Scientific Advisory Board - Business Wire
Geode Capital Management LLC Purchases 66,170 Shares of Quince Therapeutics, Inc. (NASDAQ:QNCX) - Defense World
Quince Therapeutics, Inc. (NASDAQ:QNCX) Receives $8.67 Average Target Price from Analysts - Defense World
Pharma Innovator Unlocks Multi-Disease Treatment Potential - Streetwise Reports
Quince Therapeutics’ (QNCX) “Buy” Rating Reaffirmed at D. Boral Capital - Defense World
Quince Therapeutics, Inc. (NASDAQ:QNCX) Receives $8.67 Consensus Target Price from Brokerages - MarketBeat
Quince Therapeutics' (QNCX) "Buy" Rating Reiterated at D. Boral Capital - MarketBeat
Spotlight On US Penny Stocks For January 2025 - Simply Wall St
Research Analysts Offer Predictions for QNCX FY2024 Earnings - Defense World
Brokers Set Expectations for QNCX FY2024 Earnings - MarketBeat
Quince Therapeutics initiated with a Buy at Brookline - MSN
This Box Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
Quince Therapeutics (NASDAQ:QNCX) Earns Buy Rating from Analysts at Brookline Capital Management - MarketBeat
Brookline initiates coverage on Quince Therapeutics shares, sees favorable risk-reward - Investing.com
Quince Therapeutics, Inc. (NASDAQ:QNCX) Sees Large Increase in Short Interest - MarketBeat
Atyr PHARMA (NASDAQ:ATYR) vs. Quince Therapeutics (NASDAQ:QNCX) Critical Survey - Defense World
Quince Therapeutics, Inc. (NASDAQ:QNCX) Short Interest Down 23.8% in November - MarketBeat
QNCX (Quince Therapeutics) Net Issuance of Preferred Stock : $0.00 Mil (TTM As of Sep. 2024) - GuruFocus.com
Critical Survey: Amgen (NASDAQ:AMGN) and Quince Therapeutics (NASDAQ:QNCX) - Defense World
QNCX stock touches 52-week high at $2.14 amid robust gains By Investing.com - Investing.com South Africa
Maxim Group Initiates Coverage of Quince Therapeutics (QNCX) with Buy Recommendation - MSN
QNCX stock touches 52-week high at $2.14 amid robust gains - Investing.com
Short Interest in Quince Therapeutics, Inc. (NASDAQ:QNCX) Rises By 23.0% - MarketBeat
QNCX Stock Soars to 52-Week High, Reaching $1.79 Amidst Strong Growth - Investing.com Australia
Quince Therapeutics regains Nasdaq compliance - Investing.com
Quince Therapeutics Inc Stock (QNCX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Quince Therapeutics Inc Stock (QNCX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Thye Dirk | CEO AND CHIEF MEDICAL OFFICER |
Aug 29 '24 |
Buy |
0.69 |
77,500 |
53,475 |
766,941 |
| Ryan Charles S. | PRESIDENT |
Aug 20 '24 |
Buy |
0.65 |
48,387 |
31,452 |
122,461 |
| Hannah Brendan | CHIEF BUSINESS OFFICER AND COO |
Aug 21 '24 |
Buy |
0.63 |
30,845 |
19,337 |
296,540 |
| Hannah Brendan | CHIEF BUSINESS OFFICER AND COO |
Aug 20 '24 |
Buy |
0.60 |
5,924 |
3,579 |
265,695 |
| Hannah Brendan | CHIEF BUSINESS OFFICER AND COO |
Aug 19 '24 |
Buy |
0.58 |
2,155 |
1,250 |
259,771 |
| Hannah Brendan | CHIEF BUSINESS OFFICER AND COO |
Jun 04 '24 |
Option Exercise |
0.55 |
56,061 |
30,834 |
257,616 |
2.93%
1.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):